Sheaff Brock Investment Advisors LLC Cuts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Sheaff Brock Investment Advisors LLC lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.9% during the 1st quarter, Holdings Channel reports. The firm owned 3,891 shares of the biopharmaceutical company’s stock after selling 200 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Gilead Sciences were worth $285,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Stamos Capital Partners L.P. boosted its position in Gilead Sciences by 19.5% in the first quarter. Stamos Capital Partners L.P. now owns 36,560 shares of the biopharmaceutical company’s stock worth $2,678,000 after purchasing an additional 5,960 shares during the last quarter. Axxcess Wealth Management LLC boosted its position in Gilead Sciences by 24.5% in the first quarter. Axxcess Wealth Management LLC now owns 17,916 shares of the biopharmaceutical company’s stock worth $1,312,000 after purchasing an additional 3,521 shares during the last quarter. CreativeOne Wealth LLC lifted its position in shares of Gilead Sciences by 71.7% during the 1st quarter. CreativeOne Wealth LLC now owns 23,654 shares of the biopharmaceutical company’s stock valued at $1,732,000 after buying an additional 9,875 shares during the last quarter. Shell Asset Management Co. lifted its position in shares of Gilead Sciences by 1.7% during the 1st quarter. Shell Asset Management Co. now owns 90,047 shares of the biopharmaceutical company’s stock valued at $6,596,000 after buying an additional 1,524 shares during the last quarter. Finally, Payden & Rygel Investment Group purchased a new position in shares of Gilead Sciences during the 1st quarter valued at $196,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares in the company, valued at approximately $6,614,559.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ GILD traded up $0.50 during trading on Friday, reaching $77.01. The company’s stock had a trading volume of 7,453,639 shares, compared to its average volume of 6,033,727. The stock has a market capitalization of $95.94 billion, a PE ratio of 213.92, a P/E/G ratio of 3.26 and a beta of 0.18. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The firm has a fifty day moving average of $67.79 and a 200 day moving average of $71.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.37 EPS. Analysts expect that Gilead Sciences, Inc. will post 3.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on GILD shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 26th. HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a research report on Wednesday, April 24th. Cantor Fitzgerald dropped their price target on Gilead Sciences from $75.00 to $70.00 and set a “neutral” rating on the stock in a research report on Monday, July 22nd. Oppenheimer reaffirmed an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a research report on Friday, April 19th. Finally, Barclays dropped their price target on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research report on Monday, April 29th. Twelve investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $81.81.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.